Asston Pharmaceuticals (BOM:544445) Total Receivables: ₹385.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544445 Asston Pharmaceuticals Ltd BOM:544445
19 GF Score
Price ₹67.00
! 3 Warning Signs
View Full Analysis

What is Asston Pharmaceuticals Total Receivables?

Asston Pharmaceuticals BOM:544445 -0.59% 19 Total Receivables is ₹385.2 Mil as of Mar. 2026. GuruFocus rates BOM:544445 with a GF Score™ of 19/100. The stock has 3 warning signs investors should review.

Asston Pharmaceuticals's Total Receivables for the quarter that ended in Mar. 2026 was ₹385.2 Mil.

Asston Pharmaceuticals Total Receivables Related Terms

Asston Pharmaceuticals Total Receivables Historical Data

* Premium members only.

The historical data trend for Asston Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Asston Pharmaceuticals Total Receivables Chart

Asston Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Total Receivables
64.03 86.09 161.52 245.60 385.19

Asston Pharmaceuticals Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Receivables Get a 7-Day Free Trial 161.52 0.00 245.60 368.94 385.19
BOM:544445
19GF Score
Asston Pharmaceuticals Ltd BOM:544445
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Asston Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹385.2 Mil mean?
Asston Pharmaceuticals (BOM:544445) has a Total Receivables of ₹385.2 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Asston Pharmaceuticals and its competitors.
Is Asston Pharmaceuticals' Total Receivables too high?
Asston Pharmaceuticals' current Total Receivables is ₹385.2 Mil. Overall, Asston Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Asston Pharmaceuticals' Total Receivables compare to ZTS?
Asston Pharmaceuticals' Total Receivables of ₹385.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Asston Pharmaceuticals and its competitors. Asston Pharmaceuticals's current Total Receivables is ₹385.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asston Pharmaceuticals stock overvalued right now?
Asston Pharmaceuticals (BOM:544445) has a current Total Receivables of ₹385.2 Mil. The current Total Receivables is ₹385.2 Mil. Asston Pharmaceuticals' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Asston Pharmaceuticals (BOM:544445), the current Total Receivables is ₹385.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Asston Pharmaceuticals Business Description

Address Plot No 42A, Sector-11, 4th Floor, Office No. A-431 Balaji Bhavan, CBD Belapur, Navi Mumbai, Thane, MH, IND, 400 614
Asston Pharmaceuticals Ltd manufactures and exports pharmaceutical and nutraceutical products. The company produces a wide range of healthcare items including tablets, capsules, syrups, sachets, ointments, creams, gels, and lotions. It serves markets in West and South Africa, with expansions planned into Asian countries. Asston conducts business through export sales, contract manufacturing and loan license arrangements via merchant exporters, and domestic sales within India. Revenue is generated through the sale of branded and generic pharmaceutical formulations along with nutraceutical products. The business operations are broadly categorized into: Domestic Formulations, Export Formulations, APIs and Intermediates, and Research and Development.
19GF Score

Get the complete analysis for BOM:544445

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹67.00
Price